Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022008723 - DIAGNOSIS OF ALLOGRAFT ANTIBODY-MEDIATED REJECTION

Publication Number WO/2022/008723
Publication Date 13.01.2022
International Application No. PCT/EP2021/069176
International Filing Date 09.07.2021
IPC
C12Q 1/6883 2018.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
G01N 33/50 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Applicants
  • FUNDACIÓ INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL) [ES]/[ES]
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US]/[US]
Inventors
  • BESTARD MATAMOROS, Oriol
  • SARWAL, Minnie
  • PINEDA SAN JUAN, Silvia
  • SUR, Swastika
  • SIROTA, Marina
Agents
  • ZBM PATENTS - ZEA, BARLOCCI & MARKVARDSEN
Priority Data
20382620.109.07.2020EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) DIAGNOSIS OF ALLOGRAFT ANTIBODY-MEDIATED REJECTION
(FR) DIAGNOSTIC DU REJET D'ALLOGREFFE INDUIT PAR LES ANTICORPS
Abstract
(EN) The application refers to biomarkers for diagnosing renal allograft antibody-mediated rejection. The application also refers to an in vitro method for diagnosing renal allograft antibody-mediated rejection in a patient, the method comprising determining in an isolated sample from the patient the level of expression of SIGLEC17P and/or of at least one of its associated downstream coding genes selected from the group consisting of AP4S1, ZMYM6, USP21, DMAP1, SUPT5H, TP53BP1, NECAB3, BTD, DACT1, and combinations thereof, wherein when the level of expression of SIGLEC17P and/or of at least one of its associated downstream coding genes is higher than a reference value, this is indicative of renal allograft antibody-mediated rejection.
(FR) La présente invention concerne les biomarqueurs permettant de diagnostiquer le rejet induit par les anticorps des allogreffes rénales. La présente invention concerne également un procédé in vitro pour diagnostiquer le rejet induit par les anticorps d'une allogreffe rénale chez un patient, le procédé comprenant la détermination, dans un échantillon isolé provenant du patient, du niveau d'expression de SIGLEC17P et/ou d'au moins un de ses gènes codants associés en aval, choisi dans le groupe constitué parAP4S1, ZMYM6, USP21, DMAP1, SUPT5H, TP53BP1, NECAB3, BTD, DACT1, et leurs combinaisons, dans lequel, lorsque le niveau d'expression de SIGLEC17P et/ou d'au moins un de ses gènes codants en aval associés est supérieur à une valeur de référence, cela indique un rejet induit par les anticorps d'une allogreffe rénale.
Related patent documents
Latest bibliographic data on file with the International Bureau